94% gross margins on restated net revenue. Seven consecutive profitable quarters. FDA inspection with zero nonconformances. Audit resolved. Clinical pipeline building with two randomized controlled trials advancing simultaneously in diabetic foot ulcers and venous leg ulcers; both Medicare-reimbursable indications. Share count at 16.5M diluted with no toxic convertible structures.
BioStem Technologies makes amniotic tissue products for wound care and bills Medicare for them. The gross margin on that business runs 94 percent on an annual basis. 97 percent in Q4 2025 alone. That number is not adjusted into existence. It reflects what happens when a proprietary clinical product gets billed through an established reimbursement code with minimal cost of goods. Q4 2025 net revenue came in at $10.1M. Q3 at $10.5M. Q2 at approximately $11.3M on a restated basis. These are not aspirational forecasts; they are reported figures on filed financial statements that have already been through the restatement process and emerged clean on the other side.
The restatement is the most important context here. BioStem filed restated financials in November 2025 covering Q1 2024 through Q2 2025. The reclassification moved bona fide services fees from Sales and Marketing expense into contra-revenue; reducing reported gross and net revenue materially but leaving EBITDA, net income, and cash flow unchanged. This is an accounting presentation change, not a business change. The cash that came in stayed in. The products that went out to patients still went out. The Medicare reimbursement checks that arrived in the bank account still arrived. The restatement changed which line those checks appear on in the income statement. That distinction matters enormously for anyone evaluating the financial health of the company versus the accounting presentation of it.
The Human Translation: The Accounting Reclassification. Imagine a restaurant that was counting tip pooling as revenue. The auditors said it should be counted as a reduction of revenue instead. The restaurant still made the same money. The same food went out. The same customers paid. But the revenue line on the statement looks smaller now. That is the BioStem restatement. Same business, different line items. The confusion it created in the market; the selloff, the uncertainty, the assumption that something was fundamentally wrong; was a reaction to the optics of a restatement, not to any change in the underlying cash economics of the business. The company did not lose money. It reclassified how it reports money it already received.
The FDA completed an inspection of BioStem's facility in Q3 2025 with zero nonconformances and zero observations. That is the best possible outcome from a regulatory inspection; not 'we addressed the issues' but 'there were no issues.' For a company that has been under restatement scrutiny, a clean FDA inspection is significant independent validation of operational integrity. The FDA does not coordinate with auditors. They walk into the facility, inspect the manufacturing processes, review the quality management system, and issue findings based on what they observe. Zero findings means the facility passed the most rigorous standard the FDA applies to medical device manufacturing. That result stands on its own regardless of what the accounting presentation looks like.
The clinical pipeline is advancing on two fronts simultaneously. A randomized controlled trial in diabetic foot ulcers posted positive top-line results and was submitted to CMS for consideration in coverage determination. A venous leg ulcer RCT has enrollment ahead of schedule with top-line data expected Q1 2026. Product volume grew 40 percent quarter-over-quarter in Q3 2025. The business is not standing still; it is building the clinical evidence base that will support expanded reimbursement and new indications while the existing reimbursement business generates cash at 94 percent gross margins.
The Medicare reimbursement model deserves closer examination because it is the structural driver of the 94 percent gross margin. BioStem's amniotic tissue products are billed to Medicare under established HCPCS codes for skin substitutes used in wound care. The reimbursement rate is set by CMS; the Centers for Medicare and Medicaid Services, based on clinical evidence and cost data. Once a product is assigned a billing code and reimbursement rate, the revenue per unit is predictable and contractual. The cost of goods for processed amniotic tissue is inherently low because the raw material; placental tissue; is donated by consenting mothers after cesarean delivery. Processing is the primary cost, and at BioStem's current production volume, the per-unit processing cost is a fraction of the reimbursement rate. This is not a margin that compresses with scale; it improves with scale because the fixed costs of processing are spread across more units.
The competitive landscape in advanced wound care is relevant context. Organogenesis, MiMedx, and Smith and Nephew all compete in the skin substitute and advanced wound care market. However, the micro-cap segment of this market; where BioStem operates; is populated with companies that either do not have the clinical data, do not have the manufacturing quality, or do not have the reimbursement infrastructure that BioStem has built. The combination of a clean FDA inspection, two active RCTs generating clinical evidence, established Medicare reimbursement codes, and seven consecutive profitable quarters creates a profile that is rare among wound care companies at any market capitalization, let alone in the OTC micro-cap tier. The moat is not brand; it is regulatory and clinical infrastructure.
The capital structure is unusually clean for an OTC-listed biotech. Diluted shares outstanding are approximately 16.5 million. There are no toxic convertible note structures in the capitalization table. There is no history of death spiral financing or serial dilution (new shares that shrink each existing holder's stake) through below-market placements. The share count has been relatively stable through the restatement period, which means the company did not need to issue emergency equity to survive the accounting disruption. That tells you something about the cash generation of the underlying business; it funded itself through a period of uncertainty without diluting shareholders to keep the lights on.
The risk factors are real and should not be minimized. First, Medicare concentration: the vast majority of BioStem's revenue comes from a single payer; the federal government. Any change to CMS reimbursement rates for skin substitutes, or any change in the coverage determination process, would directly impact revenue per unit. Second, the restatement itself: while the financial impact was a presentation change, the reputational impact with auditors, investors, and potential institutional holders is not zero. Companies that have restated financials face elevated scrutiny on all subsequent filings. Third, clinical trial risk: the VLU RCT top-line data expected in Q1 2026 is a binary event. Positive data strengthens the thesis materially. Negative or inconclusive data raises questions about whether the clinical evidence base can support the reimbursement expansion the thesis requires.
The product volume growth trajectory provides additional context. A 40 percent quarter-over-quarter increase in product volume during Q3 2025 suggests that the commercial team is executing on distribution expansion while the clinical team advances the RCTs. This is the right organizational dynamic; the existing product generates cash that funds clinical development, and the clinical development generates evidence that supports reimbursement expansion, which in turn drives further commercial growth. The flywheel is visible in the quarterly numbers. Whether it continues to accelerate depends on the Q1 2026 VLU data readout and any updates to the CMS submission process for the DFU trial results.
Dossiers, weekly roundup editions, and podcast notes. Free. No paywall. Unsubscribe anytime.